UNCY unicycive.com: Company Value to Revenue Ratio

Official company branding of unicycive.com (UNCY)

Unicycive Therapeutics (UNCY) generates revenue from the therapy of dialysis patients with renal failure. The price-to-sales ratio on GURU.Markets reflects market expectations, where the 0.00 metric indicates the asset's status. The business foundation relies on outsourced production via CDMOs, while patent protection and FDA requirements create a robust defensive barrier for the monopolist.

UNCY Unicycive Therapeutics: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

Unicycive Therapeutics, Inc - analytical breakdowns and key metrics (UNCY)

- current quotes and average value forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Fundamental company valuation:UNCY (Unicycive Therapeutics, Inc.)
Core merchandise of Unicycive

This ratio determines the investment attractiveness of Unicycive Therapeutics (UNCY) by comparing the Enterprise Value to annual revenue, excluding debt load. By analyzing the company's value-to-revenue dynamics, an investor can discern market expectations for the commercialization of Renazorb for the treatment of hyperphosphatemia, where sharp peaks in the indicator signal an overvaluation of future successes in the nephrology segment.